BioAgilytix Is Re-approved and Registered For The French Research Tax Credit (CIR)

The Latest News from BioAgilytix

BioAgilytix Announces Several Promotions within Its Leadership Team
1 January, 2019

BioAgilytix Announces Several Promotions within Its Leadership Team

BioAgilytix has announced several promotions within its leadership team. PD Dr. Arno Kromminga has been promoted to Global Chief Scientific Officer, and will lead BioAgilytix’s global scientific strategy while also continuing to serve as the European Managing Director. Beth Heinz has been promoted to Vice President of Global Business Development and will continue her focus on cultivating and managing both strong client relationships and strategic partnerships worldwide.

Read More

COBEPA BioAgilytix partnership
2 November, 2018

BioAgilytix to be Acquired by Private Investment Company Cobepa

BioAgilytix has announced an agreement to be acquired by Cobepa S.A., a privately-held investment company. The acquisition by Cobepa will provide BioAgilytix with increased funding and resources to meet growing demand for its high-quality services, driven by its strong scientific reputation and leading expertise in biologics development.

Read More

Fast 50 logo
3 October, 2018

BioAgilytix Recognized as a Triangle Business Journal 2018 Fast 50 Winner

BioAgilytix has been named as one of Triangle Business Journal’s Fast 50 Award winners for 2018. This award is designed to honor those privately held companies in the Triangle Park area that have demonstrated remarkable growth in the past three years.

Read More

Marshall University - Career Session and Recruiting Event Aimed at Science Majors
25 September, 2018

BioAgilytix and Marshall University Team Up for Career Session and Recruiting Event Aimed at Science Majors

BioAgilytix and Marshall University are partnering to host a career information session and recruitment event for science majors at Marshall’s Huntington, West Virginia campus on October 18, 2018. The event is aimed at educating students with degrees in Biology, Chemistry, and related science fields on the career opportunities available to them in the pharmaceutical and biotechnology industry, including within contract research organizations (CROs) such as BioAgilytix.

Read More

BioAgilytix USA Headquarters
18 September, 2018

BioAgilytix Announces Extensive Facilities Expansion Plan at Its USA Headquarters

BioAgilytix has announced a new expansion plan for its USA headquarters located in the Research Triangle area of North Carolina. The company will be developing out an additional 21,173 square foot building directly adjacent to its existing facility – nearly half of which will be dedicated laboratory space – to bring the campus’ total footprint to over 69,000 square feet.

Read More

BioAgilytix award - Inc. 5000
15 August, 2018

BioAgilytix Named to Inc. Magazine’s Inc. 5000 List of Fastest-Growing Private U.S. Companies for Fifth Time

For the Fifth Time in Six Years, the Bioanalytical Laboratory Earns an Exclusive Ranking AUGUST 15, 2018—Durham, NC—BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large…

Read More

13 August, 2018

BioAgilytix Recognized by Triangle Business Journal as a 2018 Leader in Diversity

The Bioanalytical Laboratory is Honored with Award for the Third Time, Highlighting the Company’s Ongoing Commitment to Diversity in the Workplace AUGUST 13, 2018—Durham, NC—BioAgilytix, a leading provider of contract…

Read More

17 July, 2018

BioAgilytix Remains Committed to Diversity as Global Growth Accelerates

Inclusive Diversity Policies and Programs Help the Company to Recruit a Wide Variety of Global Talent to its USA and European Headquarters JULY 17, 2018—Durham, NC—BioAgilytix, a leading provider of…

Read More

11 July, 2018

Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xB3™-001, Bioasis’ Lead Investigational Candidate to Treat HER2+ Brain Cancer, to IND Submission and into the Clinic

JULY 11, 2018—Richmond, BC, Guilford, CT and Durham, NC—Bioasis Technologies, Inc. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its xB3™ proprietary platform technology for the delivery of therapeutics across the blood-brain…

Read More